Position statement from Aplar

Care for Patients with Rheumatic Diseases During COVID-19 Pandemic

– A Position Statement from APLAR

Authors

Lai-Shan Tam¹, Yoshiya Tanaka², Rohini Handa³, Chi-Chen Chang⁴, Yew Kuang Cheng^5,6, Nazrul Isalm⁷, Mengtao Li⁸, Jose Paulo Lorenzo⁹, Yeong-Wook Song¹⁰, Kazuhiko Yamamoto¹¹, Xiaofeng Zeng⁸,  Syed Atiqul Haq¹²

Authors affiliation

¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong

²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

³Apollo Indraprastha Hospitals, New Delhi, India

⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.  

⁵Allergy, Arthritis & Rheumatism Clinic, Farrer Park Hospital

⁶Yong Loo Lin School of Medicine, National University of Singapore

⁷Dept. of Rheumatology, BSMMU, Dhaka, Bangladesh 

⁸Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, China 

⁹_{Makati Medical Center, Philippines}

¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

¹¹Laboratory for Autoimmune diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

¹²BSM Medical University, Dhaka, Bangladesh 

Correspondence

Professor Syed Atiqul Haq
BSM Medical University, Dhaka, Bangladesh
Email: haqsyedatiqul@gmail.com

The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in China in December 2019. This disease now affects the whole world. Patients with rheumatic diseases are at higher risk of respiratory infections including influenza and pneumococcal pneumonia, which is attributed to the underlying disease, comorbidities and immunosuppressive therapy (1), but to date we lack good information about the virus SARS-CoV-2.  Nonetheless, immunosuppressive treatments are essential to control disease activity and prevent functional deterioration in these patients. Rheumatologists need to be vigilant in preventing rheumatic disease patients from contracting the disease during this pandemic, especially patients with chronic lung problems (e.g. scleroderma with lung fibrosis) and chronic kidney disease (e.g. lupus nephritis) and those on high dose glucocorticoids and immunosuppressants. (Panel 1)

In the desperate search to find effective treatments for COVID-19, drugs largely used by rheumatologists have entered the spotlight, including the caution against use of non-steroidal anti-inflammatory drugs (NSAIDs), the potential of antimalarials and biologic disease-modifying anti-rheumatic drugs (bDMARDs) e.g. anti-interleukin-6 (IL-6) and targeted synthetic DMARDS (tsDMARDs) Janus kinase (JAK) inhibitors to manage cytokine storm syndrome (CSS)/cytokine release syndrome associated with COVID-19. Here, we try to provide guidance regarding clinical decision making both for patients with COVID-19 and those with rheumatic diseases, and strategies to mitigate further harm to these patients.

Methods:

An Asia Pacific League Against Rheumatism (APLAR) COVID-19 task force comprising rheumatologists from 9 Asia Pacific countries was convened on March 31, 2020. A set of guidance statements was developed and refined based on best available evidence up to April 26, 2020 and expert opinion. Given the overall limited nature of the data, a systematic review was not performed. The final guidance statements integrate both the task force members’ assessment of the evidence quality and the ratio of risk and benefit from the treatment or action. We assert that the key guiding principle should be to “first do no harm,” especially given the unknown efficacy of proposed DMARDs and biologics and their established potential harms. This guidance document has been reviewed and endorsed by the APLAR executive committee and the APLAR scientific committee chairpersons.

How can we minimize the risk of rheumatic disease patients from exposure to COVID-19?

In the absence of a vaccine or a therapeutic agent, a “mitigation approach”, including “social-distancing”, frequent hand washing and quarantining strategies are the primary intervention to hamper the spread of infection (2).  Another approach, known as “suppression strategies” includes strict lockdown measures – social distancing in entire populations, the closure of schools and community spaces, aggressive case finding and contact tracing, have succeeded in maintaining low case counts of COVID-19. During this extraordinary time, the rheumatology community faces unprecedented challenges as care could be postponed/delayed or handled through virtual care to minimize contact exposure and practice social distancing.

Comorbid conditions were common in patients with COVID-19 (3). Smoking can cause an increase in the release of IL-6  in bronchial epithelial cells (4), and upregulate angiotensin-converting enzyme-2 (ACE2) receptor, the known receptor for SARS-CoV (5). This is particularly relevant as some of the Asia Pacific countries, e.g. China, has a high male smoking rate (6). Globally the quality of evaluation, monitoring and treatment of comorbidities in rheumatic disease patients is variable with considerable scope for improvement (7). Rheumatologists should be vigilant in assessing and managing comorbidities not only to improve morbidity and mortality, but hopefully may minimize risk of COVID-19 in rheumatic disease patients.

Non-steroidal anti-inflammatory drugs (NSAIDs)

In patients with acute respiratory tract infections, short-term use of NSAIDs are associated with increased risk of cardiovascular events and nephrotoxicity (8-10), higher rates of complications, and delays in the prescription of effective antibiotic treatment (11). Despite the lack of evidence relating specifically to people with COVID-19, regular NSAID use should not be recommended as the first line option for managing the symptoms of COVID-19 (12). Nonetheless, arthritis patients taking NSAID for symptomatic relief should continue their treatment as needed.

Use of Immunosuppressants and Risk of COVID-19 Infection

Epidemiologic studies identified advanced age, male sex and presence of comorbidities (hypertension, obesity, diabetes, coronary heart disease, chronic obstructive lung disease and chronic kidney disease) as poor prognostic factors for COVID-19 (13). Despite the lack of data on the true prevalence and risk of COVID-19 in rheumatic disease patients, immunosuppressed status (the use of chemotherapy or conditions requiring immunosuppressive treatment) was not reported to be a risk factor and risk of adverse outcome. One patient with systemic sclerosis-associated interstitial lung disease (SSC-ILD) on tocilizumab and 7 patients on bDMARDs or tsDMARDs who developed COVID-19 recovered uneventfully (14-16). Nonetheless, at least two patients on rituximab (17) developed respiratory failure and one of them died despite treatment with tocilizumab (18). In order to gather real-world data to inform treatment strategies and better characterise individuals at increased risk of infection, the COVID-19 Global Rheumatology Alliance has successfully developed online portals and case report forms to enable healthcare providers around the world to enter information on individuals with rheumatic disease who have been diagnosed with COVID-19, with clinical data of the first 110 patients published (19). For now, patients with stable rheumatic diseases should continue their treatment. In case of infection (including COVID-19), treatment of infection gains precedence and immunosuppressive treatment may be de-escalated or temporarily withheld in consultation with the treating rheumatologist. (Panel 1)

Glucocorticoid Therapy

Acute lung injury and acute respiratory distress syndrome (ARDS) are partly caused by host immune responses.  Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation or cytokine storm syndrome (CSS). COVID-19 infection with CSS typically occurs in subjects with ARDS and historically, non-survival in ARDS was linked to sustained interleukin-6 (IL-6) and IL-1 elevation (20). Corticosteroids suppress lung inflammation but also inhibit immune responses and pathogen clearance. The effectiveness of adjunctive glucocorticoid therapy in the management of COVID-19 infected patients remains controversial (21, 22). Until results from ongoing randomized-controlled trials are available, the World Health Organization (WHO) has advised against routine use of systemic corticosteroids for treatment of viral pneumonia outside of clinical trials unless they were indicated for other reasons (e.g. septic shock) (Panel 2). In rheumatic disease patients on long-term steroid, it is very important to remind them not to stop their prednisone even if they develop symptoms suggestive of COVID-19 (Panel 1). For patients with active rheumatic disease, after excluding concurrent active infection, the prednisone dose could be increased carefully according to the severity of the organ manifestation, in spite of the risk of COVID-19.

Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)

Preclinical and limited clinical data suggested that HCQ and chloroquine (CLQ) have antiviral activity against SARS–CoV-2 (23-25). In contrast, a small but randomised study from China in patients with mild to moderate COVID-19 treated with HCQ or placebo found no difference in recovery rates (26), and French investigators failed to confirm antiviral activity or clinical benefit of the HCQ and azithromycin combination in 11 hospitalised patients with severe COVID-19 (27). In a French series of 17 SLE patients with COVID-19 on long-term HCQ, 11 (65%) and 5 (29%) developed respiratory failure and ARDS respectively despite having blood HCQ concentrations within therapeutic range for the management of SLE (28). Whether this blood HCQ concentrations may be effective for the antiviral activity against SARS–CoV-2 remained uncertain. Nonetheless, data from this study suggests that HCQ may not be able to prevent severe COVID-19 in these patients. Food and drug administration (FDA) cautioned against use of HCQ or CLQ for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems (Panel 2). The APLAR task force agreed that there are insufficient clinical data to recommend either for or against HCQ or CLQ for COVID-19, clinicians should monitor the patient for adverse effects, especially prolonged QTc interval. Health authorities should ensure adequate supply of these drugs since the HCQ shortage not only will limit availability to patients with COVID-19 if efficacy is truly established but also represents a real risk to patients with rheumatic diseases.

On the other hand, rheumatologists should remind patients to continue HCQ and not to taper the dosage even if they develop symptoms suggestive of COVID-19 and reassurance should be given that this drug should not increase their risk of infection.

Biologic DMARDs

Once hospitalized, for some patients with COVID-19, death can occur within a few days, many with ARDS, and some with multi-organ dysfunction syndrome (MODS) (14). In those critically ill patients, there are both clinical signs and symptoms, as well as laboratory abnormalities, that suggest a CSS is occurring in response to the viral infection. According to data from the Chinese cohorts, patients with severe disease and requiring intensive care often show leucopenia, lymphopenia, significantly higher levels of C-reactive protein (CRP), IL-6, IL-10, and tumour necrosis factor- α (TNF-α) (29).  In this setting, biologic drugs selectively blocking inflammatory cytokines, such as TNF-α inhibitors, anti-IL6, anti-IL1 and JAK inhibitors are currently employed in the treatment of severe cases of COVID-19 in an experimental manner or undergoing clinical trials (Panel 2).

Tocilizumab, has been shown effective in treating CSS, a common complication of CAR-T cell therapy used for treating refractory acute lymphoblastic leukemia (30)  and may be effective in Chinese COVID-19 patients with severe and critical disease (31). Anti-IL-6R antibody is currently included in the treatment recommendation for Chinese COVID-19 patients (Panel 2). These concepts have led to interests in JAK inhibitors, e.g Baricitinib, as potential treatments for CSS complicated with severe COVID-19.

ACE2 is a cell-surface protein widely existed on cells in the heart, kidney, blood vessels, especially alveolar epithelial cells. SARS-CoV-2 was believed to invade and enter lung cells through ACE2 mediated endocytosis. One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). AAK1 inhibitors can interrupt the passage of the virus into cells and can be helpful in preventing virus infections. Baricitinib, apart from being a JAK inhibitor, is also an AAK1 inhibitor. Baricitinib was thought to be a possible candidate for treatment of COVID-19, considering its relative safety and high affinity (32). On the other hand, JAK–STAT signal blocking by baricitinib produces an impairment of interferon-mediated antiviral response, with a potential facilitating effect on the evolution of SARS-CoV-2 infection, and therefore may not be a suitable treatment (33). While we are waiting for the results from the control trials to resolve this controversy, rheumatologists should be particularly cautious of serious infectious events on the use of this agent, in particular viral infection e.g. herpes zoster.

Conclusions

Rheumatologists worldwide are trying new strategies to optimize care for rheumatic disease patients during this unprecedented COVID-19 pandemic. Concerted efforts from health care providers in different health care systems are required to continue clinical assessments and ensure adequate supply of immunosuppressive therapy. Worsening of rheumatic disease may induce a systemic inflammatory state which may represent an adjunctive risk factor for major susceptibility to viral infection. On the other hand, rheumatologists are cautiously enthusiastic that a variety of immune-modulating drugs and targeted cytokine inhibitors available for rheumatic disease patients may also benefit patients as prophylaxis for COVID-19 or with COVID-19 induced CSS. Because of insufficient data, APLAR could not recommend any specific treatments for patients with COVID-19. Nevertheless, rheumatologists/immunologists are expert in the use of these agents and we should be to the forefront in advising around their application noting risks and benefits are not yet clear and should not be taken for granted in COVID-19. We emphasize the ongoing importance of critical review of emerging literature to inform current and future treatment decisions. International registries have been created to collect data on rheumatic patients with COVID-19. Ultimately, time and these registries will tell what the right decision is regarding maintaining current therapy for patients with rheumatic diseases. The APLAR task force will respond quickly and efficiently to place the evidence base behind and update our recommendations should new findings emerge from clinical trials.

References

1. Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD open. 2019;5(2):e001041-e.
2. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. The Lancet Infectious Diseases. 2020.
3. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020;8(1):e35-e.
4. Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. Int J Chron Obstruct Pulmon Dis. 2018;13:989-1000.
5. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). Journal of Clinical Medicine. 2020;9(3):841.
6. Zhi K, Wang L, Han Y, Vaughn MG, Qian Z, Chen Y, et al. Trends in Cigarette Smoking Among Older Male Adults in China: An Urban–Rural Comparison. Journal of Applied Gerontology. 2019;38(6):884-901.
7. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases. 2014;73(1):62-8.
8. Wen Y-C, Hsiao F-Y, Lin Z-F, Fang C-C, Shen L-J. Risk of stroke associated with use of nonsteroidal anti-inflammatory drugs during acute respiratory infection episode. Pharmacoepidemiology and Drug Safety. 2018;27(6):645-51.
9. Wen Y-C, Hsiao F-Y, Chan KA, Lin Z-F, Shen L-J, Fang C-C. Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. The Journal of Infectious Diseases. 2017;215(4):503-9.
10. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology. 2017;18(1):256.
11. Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients. Journal of Clinical Medicine. 2019;8(6):786.
12. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.
13. Lai C-C, Liu YH, Wang C-Y, Wang Y-H, Hsueh S-C, Yen M-Y, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection. 2020.
14. Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Annals of the Rheumatic Diseases. 2020:annrheumdis-2020-217442.
15. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the Rheumatic Diseases. 2020:annrheumdis-2020-217424.
16. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Annals of the Rheumatic Diseases. 2020:annrheumdis-2020-217615.
17. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, MARIA ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Annals of the Rheumatic Diseases. 2020:annrheumdis-2020-217549.
18. Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. The Journal of Rheumatology. 2020:jrheum.200507.
19. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020:10.1016/S2665-9913(20)30095-3.
20. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews. 2020:102537.
21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
22. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473-5.
23. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020;6(1):16.
24. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-71.
25. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020:105949.
26. CHEN Jun LD, LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(1):0-.
27. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses. 2020.
28. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Annals of the Rheumatic Diseases. 2020:annrheumdis-2020-217566.
29. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. The Journal of Clinical Investigation. 2020.
30. Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, et al. Management of cytokine release syndrome related to CAR-T cell therapy. Frontiers of Medicine. 2019;13(5):610-7.
31. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020:202005615.
32. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020;395(10223):e30-e1.
33. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious Diseases. 2020.